Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Treponemal Subspecies Discriminated by LAMP

By LabMedica International staff writers
Posted on 26 Apr 2018
Human yaws is a tropical skin disease of children caused by the bacterium Treponema pallidum subsp. pertenue (TPE). Skin ulcers are the most characteristic clinical manifestations associated with infection in all three active disease stages, primary, secondary, and tertiary yaws.

Although it is possible to distinguish current infection, active or latent, from past infection when non-treponemal and treponemal tests are used in combination, it remains impossible based on serology and in some instances clinical manifestations, to differentiate yaws infection (TPE) from syphilis, caused by subsp. pallidum (TPA) or bejel, caused by the subsp. endemicum (TEN).

A team of scientists working with the Institute for Primate Research (Göttingen, Germany) used loop-mediated isothermal amplification (LAMP) assays to rapidly differentiate infection with any of the three Treponema pallidum subspecies (pallidum (TPA), pertenue (TPE), and endemicum (TEN)) and which are known to infect humans and nonhuman primates (NHPs). Four TPA, six human, and two NHP TPE strains, as well as two human TEN strains were used to establish and validate the LAMP assays.

Three different LAMP assays were designed. First, the team generated a LAMP assay that is able to detect DNA of all three TP subspecies (TPA, TPE, and TEN). Another LAMP assay was designed to distinguish TPE strain infection from infection with TPA or TEN strains. A third LAMP assay that differentiates between infection with TPE or TEN and infection with TPA strains was established. LAMP reactions were performed using the Mast Isoplex DNA Kit. All reactions were run on a MircoAmp Fast Optical 96-well reaction plate.

The scientists reported that all three LAMP assays were highly specific for the target DNA. Amplification was rapid from 5 to 15 minutes, and within a range of 10E+6 to 10E+2 of target DNA molecules. Performance in non-human primate (NHP) clinical samples was similar to the one seen in human TPE strains. The LAMP assay targeting the gene was positive for all tested TP strain samples including the four TPA, six human TPE, two simian TPE, and the two human TEN strains. The LAMP assay that uses a part of the TP_0619 gene generated positive results for all TPE strains including simian TPE strains as well as the two human TEN strains.

The authors concluded that the newly designed LAMP assays provide proof of concept for a diagnostic tool that enhances yaws clinical diagnosis. It is highly specific for the target DNA and does not require expensive laboratory equipment. Test results can potentially be interpreted with the naked eye, which makes it suitable for the use in remote clinical settings. The study was published on April 12, 2018, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Institute for Primate Research


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.